The modern regulatory framework governing the American pharmaceutical and medical device industries relies heavily on a delicate compromise: expediting life-saving treatments to market on the condition that manufacturers rigorously study their long-term safety and efficacy afterward. Known as postmarket studies, these mandated commitments are intended to bridge the gap between initial, often limited pre-approval data and the messy reality of widespread public use. However, a comprehensive analysis of Food and Drug Administration data reveals a pervasive systemic failure. Hundreds of these crucial follow-up investigations are running years behind schedule, languishing in administrative delays, or remaining entirely unfulfilled, leaving patients, physicians, and health programs exposed to unquantified risks while profitable products remain on the market.
This chronic lack of follow-through has transformed what was meant to be an essential safety net into a vulnerable weak point in U.S. healthcare policy. While pharmaceutical giants and device manufacturers reap billions in continuous sales, the delayed delivery of real-world evidence forces doctors to make critical treatment decisions in a vacuum of uncertainty. Independent researchers and healthcare watchdogs warn that upcoming policy changes designed to fast-track approvals even further will only exacerbate the burden on an already strained post-approval oversight system.
The Anatomy of a Systemic Delay
The scope of the problem is vast. According to federal databases tracking the progress of postmarket requirements and commitments for drugs, biologics, and medical devices, nearly 600 studies are currently lagging behind their original schedules. Roughly a third of all ongoing postmarket obligations are officially designated as delayed, with more than 250 of those final reports missing deadlines that stretched past mid-2026.
These delays span a diverse array of medical innovations, touching everything from specialized surgical implants and emergency therapies to widely prescribed specialty drugs. For instance, the CustomFlex Artificial Iris—a prosthetic implant designed to replace damaged or missing irises—was approved following a 2018 review. A mandatory pediatric study meant to track patients over five years had an accepted protocol in 2019, yet federal databases show zero patients enrolled. Representatives for the German manufacturer and its U.S. distributors attribute the standstill to the extreme rarity of the underlying eye condition, known as aniridia, noting that they are actively collaborating with the FDA to find alternative methodologies to satisfy the safety requirement.
Similarly, a post-approval safety study evaluating Pfizer’s covid treatment, Paxlovid, in pregnant women missed its original completion milestone at the end of 2024. Pfizer representatives have maintained that the company is cooperating closely with regulatory authorities to submit findings as soon as practicable. In the realm of medical devices, the Scandinavian Total Ankle Replacement (STAR) system—approved alongside a clinical trial protocol in 2009—fell drastically short of its minimum enrollment target of 500 subjects, managing to enlist only 142. Nearly half of those participants experienced adverse events, resulting in dozens of secondary surgical interventions, revisions, or total device removals, underscoring the high stakes of failing to monitor medical hardware adequately once implanted in human bodies.
The High Stakes of the Tavneos Controversy
No case better illustrates the high-stakes perils and systemic vulnerabilities of the FDA’s postmarket approach than that of Tavneos, an expensive medication manufactured by Amgen subsidiary ChemoCentryx. Approved in 2021 to treat severe cases of ANCA-associated vasculitis—a collection of rare, potentially fatal autoimmune diseases that ravage blood vessels and vital organs—Tavneos cleared the regulatory hurdle despite internal warnings from FDA experts who flagged the manufacturer’s limited safety data.
In keeping with standard practice, the agency granted approval with a binding proviso: Amgen was required to conduct a rigorous, multi-year postmarket safety study involving 300 patients, each monitored for five years. That study has since stalled dramatically. By last fall, only 21 patients had been enrolled, and subsequent updates showed the total climbing to a mere 49 participants by mid-summer, severely missing milestones meant to see completion by 2030.
Meanwhile, real-world utilization surged, with Amgen estimating that global exposure to the drug has surpassed 25,000 patient-years. This widespread use brought alarming safety signals to light. The FDA has identified dozens of cases of drug-induced liver injury (DILI) that are considered possibly or probably linked to the medication—precisely the sort of long-term risk the postmarket study was designed to evaluate.
The regulatory battle over Tavneos escalated sharply when the FDA alleged that the original clinical trial data submitted by ChemoCentryx to secure initial approval was not only unconvincing but actively manipulated to mask a failure to demonstrate substantial effectiveness. Although Amgen has vigorously defended the validity of the data and denied any manipulation, international consensus has fractured. The European Union formally revoked its marketing authorization for Tavneos, and the FDA has initiated formal proceedings to pull the drug from the U.S. market. The outcome carries immense financial and medical weight: Tavneos commands a price tag exceeding $220,000 annually, representing a cornerstone investment from Amgen’s multi-billion-dollar acquisition of ChemoCentryx.
Economic Incentives for Inaction
For pharmaceutical and medical device manufacturers, the structural architecture of the regulatory timeline creates a perverse economic incentive: delay can pay. Under the current framework, companies are legally permitted to continue marketing, distributing, and profiting from their products while mandated postmarket studies stall or drag on for years.
Government audits have repeatedly highlighted the financial toll of this regulatory lag. A landmark 2022 analysis by the Department of Health and Human Services Office of Inspector General estimated that Medicare and Medicaid spent more than $18 billion between 2018 and 2021 alone on accelerated-approval drugs whose confirmatory trials remained incomplete long past their original target dates. When products command astronomical prices—such as Sarepta Therapeutics’ Exondys 51 for Duchenne muscular dystrophy, which ranges from $750,000 to $1.5 million annually and generated over $530 million in sales last year despite missed postmarket study deadlines—the financial returns on delayed research are staggering.
Industry representatives frequently point to legitimate operational hurdles to explain these timelines. Difficulties in patient recruitment, small target populations, competition with concurrent clinical trials, and patient reluctance to accept the possibility of receiving a placebo in a randomized study are cited as persistent bottlenecks. Amgen representatives noted these exact challenges in defending the sluggish progress of the Tavneos follow-up trial.
Federal Responses and Policy Implications
Defenders of the federal health apparatus argue that blanket condemnation of delayed studies ignores the complexities of clinical research. Emily Hilliard, a spokesperson for the Department of Health and Human Services, emphasized that administrative or operational delays do not inherently indicate that a medical product possesses an unresolved safety or efficacy defect. According to HHS, evaluating the significance of any missed milestone requires a rigorous, case-specific review, and the agency maintains that it exercises its enforcement powers whenever appropriate.
Nevertheless, external researchers and independent medical experts remain deeply concerned that recent policy shifts will further strain the system. In early 2026, FDA leadership announced a significant policy modification establishing a single clinical trial as the "default requirement" for agency drug approvals, moving away from the historical standard of two independent studies. While administration officials defended the move in The New England Journal of Medicine by arguing it will substantially reduce development costs, accelerate patient access, and avoid redundant research, independent analysts caution that shifting the burden of proof to the post-approval phase is a dangerous gamble.
Dr. Aaron Kesselheim, a professor at Harvard Medical School who has extensively studied postmarket surveillance, noted that reducing pre-approval testing inevitably places unprecedented pressure on an already fragile post-approval apparatus. Similarly, Dr. Sanket Dhruva, a cardiologist and associate professor of medicine at the University of California-San Francisco, describes traditional postmarket requirements as historically "toothless."
As regulatory pathways grow faster and more streamlined—exemplified by new initiatives like the Commissioner’s National Priority Voucher program, which targets ultra-fast reviews for critical health innovations—the necessity of robust, timely follow-through becomes ever more critical. Without stricter enforcement mechanisms, meaningful penalties for chronic delays, and a willingness to swiftly remove unproven or dangerous products from commerce, the system risks trading genuine medical advancement for prolonged public exposure to uncertainty, financial waste, and unverified medical claims.
